CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We examined the mechanisms of action of anti-CTLA4 and a GM-CSF-transduced tumor cell vaccine (Gvax) and their impact on the balance of effector T cells (Teffs) and Tregs in an in vivo model of B16/BL6 melanoma. Tumor challenge increased the frequency of Tregs in lymph nodes, and untreated tumors became infiltrated by CD4+Foxp3- and CD4+Foxp3+ T cells but few CD8+ T cells. Anti-CTLA4 did not deplete Tregs or permanently impair their function but acted in a cell-intrinsic manner on both Tregs and Teffs, allowing them to expand, most likely in response to self antigen. While Gvax primed the tumor-reactive Teff compartment, inducing activation, tumor infiltration, and a delay in tumor growth, the combination with CTLA4 blockade induced greater infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly correlated with tumor rejection. The data suggest that Tregs control both CD4+ and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Quezada et al., 2006
Experimental — accuracy not yet measuredIn the citing paper
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [121]
In the citing paper
“In general, anti-CTLA4 expands CD4 effector T cells (Teff) with subsequent increase in the Teff/ Treg ratio in responding tumors (22).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“In murine models, response to anti-CTLA-4 therapy was shown to be associated with an increase in the ratio of Teffs to Tregs (Quezada et al., 2006).”
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
“Later on, mechanistic studies revealed that anti-tumor activity was associated with increased ratio of both CD4 and CD8 effector cells to FoxP3 regulatory T cells (Quezada et al., 2006).”
BackgroundSelf-citationImmune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
“CTLA-4, PD-1, or PD-L1 blockade increases CD8 T-cell-toTreg ratios within the tumor, which we have previously described as being predictive of therapeutical efficacy in the B16 melanoma model (14) (Fig.”
BackgroundHallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
“showed that CTLA-4 blockade in combination with GM-CSF vaccination alters the intratumor balance of effector and regulatory T-cells (84).”
BackgroundSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
“2 C; Quezada et al., 2006; Hodi et al., 2008; Liakou et al., 2008), which is thought to drive tumor rejection given the anti- and pro-tumor growth activity of T eff and T reg cells, respectively (Griffiths et al., 2007; Quezada et al., 2008).”
BackgroundResultInfluentialSelf-citationAnti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
BackgroundFerroptosis in cancer therapy: a novel approach to reversing drug resistance
Zhang, C., Liu, X., Jin, S., Chen, Y., & Guo, R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01530-y · Cited by 1,332
“Tumor cell-intrinsic factors indicate the characteristics of tumor cells themselves, which prevent immune cell infiltration or function within the tumor microenvironment (TME).”
BackgroundInfluentialLoss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
“Manipulating an increase in the intratumoral ratio of effector to regulatory T cells in poorly immunogenic mice melanoma can overcome Treg-mediated suppression and tip the balance toward tumor rejection.(31) Therefore, a combination of depletion or attenuation of Tregs and concomitant stimulation of tumor-specific eff…”
BackgroundPeggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
“Both cell lines have been previously described (Quezada et al., 2006).”
BackgroundSelf-citationRegulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
“On the other hand, it has been reported that CTLA-4 blockade results in an accumulation of CD25þCD4þTregs and CD8þ T cells in tumor tissue.(93,94) Thus, the incorpora-”
BackgroundQuezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P. A., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091918 · Cited by 898
“Mice used for functional experiments were sacrificed on day 18 after tumor implantation, and LN cells and tumor-infiltrating lymphocytes were isolated as previously described (Quezada et al., 2006, 2008).”
Self-citationSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
“Previous data showed that anti-CTLA-4 antibody blockade results in expansion of Tregs in the lymph nodes of treated mice (9).”
BackgroundInfluentialThe emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
“However, other studies have shown an intact suppressive function in vitro of T Reg cells isolated from mic”
ResultThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citationDuraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 745
Zamarin, D., Holmgaard, R. B., Subudhi, S. K., Park, J. S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J. D., & Allison, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008095 · Cited by 711
“Scie effector to Treg ratios, which has been previously demonstrated to be a marker of a favorable immunological response to immunotherapy (29, 30).”
BackgroundRegulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
“An increased ratio of effector to regulatory T cells following anti-CTLA-4 treatment is a hallmark of successful tumor rejection (23).”
BackgroundFares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 650
“Inversion of the intratumoral ratio between CD8+ T lymphocytes and Foxp3+/CD4+ T reg lymphocytes was correlated with the effect of immunotherapy on experimental melanoma (Quezada et al., 2006), and a high CD8+/T reg cell ratio was found to be associated with a favorable prognosis in human epithelial ovarian cancer (Sa…”
BackgroundHodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
“Together, these findings help clarify the immunologic and clinical effects of CTLA-4 antibody blockade in previously vaccinated patients and raise the possibility that selective targeting of antitumor Tregs may constitute a complementary strategy for combination therapy.”
BackgroundResultSelf-citationNovel cancer immunotherapy agents with survival benefit: recent successes and next steps
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3153 · Cited by 642
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
“Importantly, the intratumor ratio of effector T cells to T reg cells was also increased, a finding that was previously shown to be a marker of a favorable immunological response to immunotherapy in murine tumor models (Quezada et al., 2006; Curran et al., 2010) and has been associated with improved survival (Bui et al.”
BackgroundRomano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
“More recently, studies in mice revealed that the antitumor activity of CTLA-4 blockade is mediated by Fc gamma receptor (FcγRIV)expressing macrophages in the tumor microenvironment (TME) via in trans depletion of tumor-infiltrating Tregs (8–10).”
BackgroundInfluential(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
“, 1996), promotes the rejection of established murine melanoma by altering the balance of T effector cells (Teff) and T regulatory cells (Treg) (Quezada et al., 2006; van Elsas et al., 1999).”
BackgroundInfluentialFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
“…that, in the context of human FcgRhuman IgG interactions in vivo, depletion of tumor-infiltrating Treg cells is a major contributor to the shift in this ratio, which has previously been associated with therapeutic responses in mouse and humans (Hodi et al., 2008; Quezada et al., 2006).”
BackgroundSelf-citationLiakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
“Mouse studies have demonstrated that an increased ratio of effector to regulatory T cells (Teff/Treg) correlates with anti-tumor responses (8).”
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 550
“correlates with antitumor immunity (59).”
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G. J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.023 · Cited by 536
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Chao, Y., Xu, L., Liang, C., Feng, L., Xu, J., Dong, Z., Tian, L., Yi, X., Yang, K., & Liu, Z. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0262-6 · Cited by 493
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 458
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
“Blockade of CTLA-4 has led to enhanced T-cell activation in animal models (5, 6), and mechanistic studies have shown that animals treated with anti–CTLA-4 have an increased ratio of effector to regulatory T cells, which correlates with tumor regression (7).”
BackgroundSelf-citationNaive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E.-K. M., Muranski, P., Restifo, N. P., & Antony, P. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 457
“T reg cells (Quezada et al., 2006, 2008; Peggs et al., 2009).”
Ku, G. Y., Yuan, J., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 422
“Therefore, blockade of CTLA-4 is thought to prevent down-regulation of T cells and can potentiate immune responses against antigens expressed on tumor cells.(10-13)”
BackgroundArce Vargas, F., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., Miranda Rota, E., Dahan, R., Georgiou, A., Sledzinska, A., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.013 · Cited by 418
“As previously described, in this system, Gvax alone failed to extend survival of tumor-bearing mice (Quezada et al., 2006; van Elsas et al., 2001).”
BackgroundResultRational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Mosely, S. I. S., Prime, J. E., Sainson, R. C. A., Koopmann, J.-O., Wang, D. Y. Q., Greenawalt, D. M., Ahdesmaki, M. J., Leyland, R., Mullins, S., Pacelli, L., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0114 · Cited by 415
“These tumor models have been invaluable in providing preclinical proof of concept for candidate immunotherapeutic drugs (16, 17), as well as building an understanding of mechanism of action and evaluating potential biomarkers of response (18, 19).”
BackgroundPiersma, S. J., Jordanova, E. S., van Poelgeest, M. I. E., Kwappenberg, K. M. C., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. M., Kenter, G. G., Fleuren, G. J., Offringa, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3388 · Cited by 414
“In comparison with lymph nodes, CD8 T cells are underrepresented in the tumor when compared with CD4 T cells and regulatory T cells (47).”
BackgroundResultRegulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
“CTLA4 blockade renders effector T cells resistant to T Reg -cell suppression, preserves the T Reg -cell intrinsic suppressive capacity and expands the pool of T Reg cell”
BackgroundNuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Serrels, A., Lund, T., Serrels, B., Byron, A., McPherson, R. C., von Kriegsheim, A., Gómez-Cuadrado, L., Canel, M., Muir, M., Ring, J. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.001 · Cited by 407
“A clinical study combining agents targeting cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4), which is thought to influence Treg function (Peggs et al., 2009; Quezada et al., 2006; Simpson et al., 2013; Wing et al., 2008), and PD-1, which blocks signals that inhibit T cell function, has reported impressive respons…”
InfluentialJayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
Charych, D. H., Hoch, U., Langowski, J. L., Lee, S. R., Addepalli, M. K., Kirk, P. B., Sheng, D., Liu, X., Sims, P. W., VanderVeen, L. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1631 · Cited by 398
“Interestingly anti–CTLA-4 was not active in the B16F10 melanoma model as a single agent (32, 33).”
BackgroundWing, J. B., Ise, W., Kurosaki, T., & Sakaguchi, S. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.006 · Cited by 388
“To confirm the effect of CTLA-4 on specific Tfh formation and IgE production, we used CTLA-4 blocking antibody (Clone 9D9) (Quezada et al., 2006) in C57BL/6 mice.”
MethodDepleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
“In murine models, response to CTLA-4 mAb therapy was shown to be correlated with an increase in the ratio of Teff cells to Treg cells [65].”
BackgroundImproved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
“Disruption of CTLA-4 and B7 interactions by mAbs with ipilimumab or tremelimumab enhances both Teff and Treg proliferation, leading to suggestions that a ratio favoring Teffs over Tregs would promote tumor regression (4, 16).”
BackgroundCD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Kim, H.-J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0216 · Cited by 380
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382
“preclinical and clinical studies (3, 6, 18, 19, 28), and it has emerged as a paradigm shift in cancer therapy.”
Nakamoto, N., Cho, H., Shaked, A., Olthoff, K., Valiga, M. E., Kaminski, M., Gostick, E., Price, D. A., Freeman, G. J., Wherry, E. J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000313 · Cited by 380
“Antibody-mediated blockade of CTLA-4 signaling can augment antigen-specific CD8 T cell responses in a CD4-independent manner, promoting anti-tumor and autoimmune effects[21,29].”
BackgroundAt the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
“In the B16 melanoma model, measurements of total Tregs or tumor-specific cytotoxic T cells in the blood did not correlate with anti-tumor activity [113].”
BackgroundHodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
“(%) Ipilimumab Plus Sargramostim (n = 123) Ipilimumab Only (n = 122) Age, median (range), y 61 (25-86) 64 (21-89)”
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S. E., Frigault, M. J., Lee, J., Posey, A. D., Scholler, J., Scholler, N., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535245 · Cited by 353
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 336
Sinicrope, F. A., Rego, R. L., Ansell, S. M., Knutson, K. L., Foster, N. R., & Sargent, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.053 · Cited by 329
Cancer and Inflammation: Promise for Biologic Therapy
Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y.-C., El-Omar, E. M., Trinchieri, G., Dubinett, S. M., Mao, J. T., Szabo, E., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32e74 · Cited by 325
“Preclinical studies have showed that the ratio of effectors to regulatory TILs determines tumor rejection.(32) Consistent with this notion, recent studies in patients with hepatocellular and ovarian carcinoma have shown that the ratio of CD8+/regulatory T cells (Treg, defined by FoxP3 expression) is an independent pro…”
BackgroundCAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Rodriguez-Garcia, A., Palazon, A., Noguera-Ortega, E., Powell, D. J., & Guedan, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01109 · Cited by 312
“In addition, the importance of the effector to regulatory T cell balance in predicting responses to immunotherapy treatments has been highlighted (182).”
BackgroundSharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
“At the present time, it is not clear whether the antitumor effects of anti–CTLA-4 ( α CTLA4) antibodies are due to their blockade of a negative regulatory signal in T effector cells (Teffs) or to their interference with Treg function (11).”
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 303
“observed that a CTLA-4 blockade with GM-CSF combination immunotherapy in an in vivo B16/BL6 mouse model of melanoma led to a self-expansion of Treg cells in tumors [47].”
BackgroundInfluentialEngagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300
Self-citationInduction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 294
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 296
“Con sistent with these results, high tumor effector T cell to T reg cell ratio correlates with better tumor prognosis and clinical bene fit of immunotherapy (Sato et al., 2005; Quezada et al., 2006; Balachandran et al., 2011).”
ResultFeatures of responding T cells in cancer and chronic infection
Kim, P. S., & Ahmed, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.02.005 · Cited by 297
“Similarly, GVAX using irradiated tumor cells combined with CTLA-4 [60] or PD-1 [61 ] blockade significantly poten-”
BackgroundCombining microenvironment normalization strategies to improve cancer immunotherapy
Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919764117 · Cited by 286
“In addition, anti–PD-1 treatment was modeled as an increase in CD8 T cells, and anti–CTLA-4 treatment was modeled as a decrease in regulatory T cells (Tregs), in line with the reported effects of these two treatments (50).”
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
Waitz, R., Solomon, S. B., Petre, E. N., Trumble, A. E., Fassò, M., Norton, L., & Allison, J. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1782 · Cited by 282
“Importantly, the intratumor ratio of Teff to Treg was also increased as a result of our treatment, which has been correlated with tumor rejection in the B16 GVAX/anti–CTLA-4 model (27).”
Duraiswamy, J., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1550 · Cited by 278
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
“In contrast, mice treated with either Gvax or anti-CTLA-4 monotherapy showed only a partial increase in the intratumor CD8 Teff ⁄ Treg cell ratio and failed to reject tumors (121).”
BackgroundInfluentialCohen, A. D., Schaer, D. A., Liu, C., Li, Y., Hirschhorn-Cymmerman, D., Kim, S. C., Diab, A., Rizzuto, G., Duan, F., Perales, M. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010436 · Cited by 261
“A similar skewed ratio has recently been reported with an agonist anti-OX40 mAb, as well as antagonist anti-CTLA4 mAb, suggesting that an altered intra-tumor Teff:Treg ratio may be predictive of anti-tumor activity of these immune-modulating approaches[22,23,30,31].”
BackgroundKavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Sitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Wolchok, J. D., & Saenger, Y. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-2 · Cited by 250
“tial enhancement of effector T-cell activity secondary to reduction in regulation [ 17 ].”
BackgroundCancer and Inflammation: Implications for Pharmacology and Therapeutics
Balkwill, F., & Mantovani, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.312 · Cited by 249
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
Fu, T., He, Q., & Sharma, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1138 · Cited by 243
“ICOSCD8T cells produce IFN-γ upon recognition of tumor antigen and the absence of ICOS results in diminished tumor antigen-specific T cell responses Since CD8 T cells have been shown to play a dominant role in tumor rejection in the B16/BL6 melanoma model treated with anti-CTLA-4 (7-9, 36), we investigated the impact…”
BackgroundMethodResultInfluentialPredicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
Rashidian, M., Ingram, J. R., Dougan, M., Dongre, A., Whang, K. A., LeGall, C., Cragnolini, J. J., Bierie, B., Gostissa, M., Gorman, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161950 · Cited by 246
“Treatment of animals having received the B16/ GVAX combination with an anti-CTLA4 antibody, administered immediately after tumor implantation, mostly results in a complete response to therapy (Quezada et al., 2006; Curran et al., 2010).”
BackgroundRegulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs, J. F., Nierkens, S., Figdor, C. G., de Vries, I. J. M., & Adema, G. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70155-3 · Cited by 245
In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice
Ali, O. A., Emerich, D., Dranoff, G., & Mooney, D. J. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000359 · Cited by 246
“Engineered PLG matrices cause regression of established melanoma Because a high ratio of CD8 T cell effectors to FoxP3 Treg cells has been linked to therapeutic tumor immunity in murine and human systems (33, 35), we tested the activity of PLG vaccines against B16-F10 tumors that had been established for 9 days (inocu…”
BackgroundMethodAnti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
Callahan, M. K., Wolchok, J. D., & Allison, J. P. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.001 · Cited by 245
Śledzińska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D. F., Ghorani, E., Akarca, A. U., Marzolini, M. A. V., Solomon, I., Vargas, F. A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.007 · Cited by 228
Self-citationRegulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Le, D. T., & Jaffee, E. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3912 · Cited by 240
“More recent studies suggest that it is T-effector (Teff)–Treg ratios that correlate with effective antitumor responses (7).”
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238
Li, B., Lalani, A. S., Harding, T. C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M. J., Simmons, A. D., & Jooss, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1558 · Cited by 232
Selby, M. J., Engelhardt, J. J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K., Yao, D., Quigley, M., Valle, J., Wang, C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161779 · Cited by 231
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 229
“Thus, while a mechanism of action of CTLA-4 blockade based entirely on interruption of cellintrinsic inhibitory function in the effector and regulatory populations could explain all of the outcomes, an additional effect on the function of the regulatory compartment in vivo could not be reliably excluded (100).”
BackgroundRational design of anti-GITR-based combination immunotherapy
Zappasodi, R., Sirard, C., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0420-8 · Cited by 227
Croci, D. O., Zacarías Fluck, M. F., Rico, M. J., Matar, P., Rabinovich, G. A., & Scharovsky, O. G. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0343-y · Cited by 226
“tumor immunity elicited by a GM-CSF-transduced melanoma vaccine [44, 98].”
BackgroundHirschhorn-Cymerman, D., Rizzuto, G. A., Merghoub, T., Cohen, A. D., Avogadri, F., Lesokhin, A. M., Weinberg, A. D., Wolchok, J. D., & Houghton, A. N. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082205 · Cited by 227
Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition
Liu, X., Mo, W., Ye, J., Li, L., Zhang, Y., Hsueh, E. C., Hoft, D. F., & Peng, G. (2018) · Nature Communications · doi:10.1038/s41467-017-02689-5 · Cited by 224
(2017) · doi:10.1158/2159-8290.cd-17-0256 · Cited by 223
“341 In addition to contributing to T cell activation, CTLA-4 blockade also helps with T cell 342 trafficking (24), while PD-1 blockade predominantly activates T cells within the tumor 343 (21).”
Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813175106 · Cited by 218
“Sensitized CD4 T cells were then tested with target APCs without peptide or pulsed with peptide in ELISPOT assays as previously described (30).”
BackgroundMethod
Metadata
- Authors
- Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Quezada, S. A.
- ORCID
- Quezada, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1935-1945
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1479425
- OpenAlex
- W2131874142
- Cited by
- 700
- References
- 50
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 44 · 2020: 35 · 2019: 37 · 2018: 41 · 2017: 46 · 2016: 29 · 2015: 41 · 2014: 41 · 2013: 39 · 2012: 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, GM-CSF, GVAX, tumor cell vaccine, regulatory T cells, effector T cells, B16-BL6 melanoma, antitumor immunity, Foxp3, CD8+ T cells, CD4+ T cells, tumor rejection, combination immunotherapy
- MeSH terms
- Animals, Antigens, Differentiation, Immunotherapy, Lymph Nodes, Melanoma, Experimental, Mice, Inbred C57BL, Antigens, CD, CD4 Antigens, T-Lymphocyte Subsets, Granulocyte-Macrophage Colony-Stimulating Factor, CD8 Antigens, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.